Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mutations in muscle phosphofructokinase gene

N Raben1, J B Sherman

  • 1Arthritis and Rheumatism Branch, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

Human Mutation
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancements in AAV-mediated Gene Therapy for Pompe Disease.

Journal of neuromuscular diseases·2019
Same author

Prophylaxis of Colds.

British medical journal·2010
Same author

Autophagy in skeletal muscle: implications for Pompe disease.

International journal of clinical pharmacology and therapeutics·2009
Same author

Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.

Molecular genetics and metabolism·2008
Same author

Detection and imaging of non-contractile inclusions and sarcomeric anomalies in skeletal muscle by second harmonic generation combined with two-photon excited fluorescence.

Journal of structural biology·2008
Same author

Role of autophagy in the pathogenesis of Pompe disease.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology·2007
Same journal

Single-Cell and Multiomics Characterization of p21 in Cancer Progression and Therapeutic Sensitivity.

Human mutation·2026
Same journal

COL1A1 and SERPINE1 as Potential Therapeutic Targets in Diabetic Retinopathy: A Study Incorporating RNA Transcriptomics, Single-Cell RNA Sequencing, and Proteomics.

Human mutation·2026
Same journal

Autosomal Dominant Missense <i>DAG1</i> Variant Linked to Mild-Moderate LGMD R16.

Human mutation·2026
Same journal

RETRACTION: "Differential Effects of AKT1(p.E17K) Expression on Human Mammary Luminal Epithelial and Myoepithelial Cells".

Human mutation·2026
Same journal

Diagnostic Yield of Genome Sequencing in an Iranian Exome-Negative Autosomal-Recessive Intellectual Disability Cohort.

Human mutation·2026
Same journal

Exploring the Functional Impact of Individual <i>DDX41</i> Variants With a Fast and Robust Cell-Based Method.

Human mutation·2026
See all related articles

Muscle phosphofructokinase (PFK) deficiency, or Tarui disease, causes exercise intolerance. Two common mutations in Ashkenazi Jewish populations facilitate molecular diagnosis.

Area of Science:

  • Biochemistry
  • Genetics
  • Metabolic Disorders

Background:

  • Muscle phosphofructokinase (PFK-M) gene mutations cause a metabolic myopathy, leading to exercise intolerance and compensated hemolysis.
  • PFK deficiency, also known as glycogenosis type VII or Tarui disease, is a rare autosomal recessive disorder.
  • Genetic heterogeneity is established, with multiple mutation types identified across diverse ethnic groups.

Purpose of the Study:

  • To investigate the genetic basis and ethnic prevalence of PFK-M deficiency.
  • To explore the feasibility of molecular diagnosis for specific populations.

Main Methods:

  • Identification of various mutations (splicing defects, frameshifts, missense) in the PFK-M gene.
  • Analysis of genotype-phenotype correlations.

Related Experiment Videos

  • Prevalence assessment in different ethnic groups, particularly Ashkenazi Jewish descent.

    • Main Results:

    • No clear correlation was found between genotype and the clinical presentation of Tarui disease.
    • PFK-M deficiency shows higher prevalence in individuals of Ashkenazi Jewish descent.
    • Two common PFK-M mutations are identifiable in Ashkenazi patients, enabling molecular diagnosis.

    Conclusions:

    • Molecular diagnosis for Tarui disease is feasible, especially in the Ashkenazi Jewish population, due to shared mutations.
    • An exon 5 splicing defect is the most frequent mutation (approx. 68%) among Ashkenazi alleles.
    • Further research into the genetic heterogeneity and ethnic-specific prevalence of PFK-M deficiency is warranted.